Metformin versus rosiglitazone in the treatment of polycystic ovary syndrome

European Journal of Obstetrics and Gynecology and Reproductive Biology

Volumn 126, Issue 1, 2006, Pages 93-98

  Mitkov, M ^a   Pehlivanov, B ^a   Terzieva, D ^a  

^a MEDICAL UNIVERSITY OF PLOVDIV   (Bulgaria)

Author keywords

Insulin resistance; Metformin; PCOS; Rosiglitazone; Thiazolidenediones

Indexed keywords

ANDROGEN; IMMUNOREACTIVE INSULIN; INSULIN SENSITIZING AGENT; METFOGAMMA; METFORMIN; PRASTERONE SULFATE; ROSIGLITAZONE; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE;

ADULT; ARTICLE; BODY MASS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; FEMALE; HORMONE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIPID METABOLISM; MORPHOMETRICS; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; TESTOSTERONE BLOOD LEVEL; TREATMENT OUTCOME;

EID: 33748042964     PISSN: 03012115     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejogrb.2005.11.019     Document Type: Article

References (28)

1. Franks S. Polycystic ovary syndrome. N Engl J Med 333 (1995) 853-861
2. Tsilchorozidou T., Overton C., and Conway G.S. The pathophysiology of polycystic ovary syndrome. Clin Endocrinol 60 (2004) 1-17
3. Nestler J.E., Jakubowicz D.J., Vargas A.F., Brik C., Quintero N., and Medina F. Insulin stimulates testosterone biosynthesis by human thecal cells from women with polycystic ovary syndrome by activating its own receptor and using inositolglycan mediators as the signal transduction system. J Clin Endocrinol Metab 83 (1999) 2001-2005
4. Mor E., Zograbyan A., Saadat P., et al. The insulin resistant subphenotype of polycystic ovary syndrome: clinical parameters and pathogenesis. Am J Obstet Gynecol 190 (2004) 1654-1660
5. Ciampelli M., Leoni F., Cucinelli F., et al. Assessment of insulin sensitivity from measurements in the fasting state and during an oral glucose tolerance test in polycystic ovary syndrome and menopausal patients. J Clin Endocrinol Metab 90 (2005) 1398-1406
6. Marsden P.J., Murdoch A.P., and Taylor R. Tissue insulin sensitivity and body weight in polycystic ovary syndrome. Clin Endocrinol 55 (2001) 191-199
7. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 18 (1997) 774-800
8. de Leo V., La Marca A., and Petraglia F. Insulin-lowering agents in the management of polycystic ovary syndrome. Endocr Rev 24 (2003) 633-667
9. Nestler J.E., Stovall D., Akhter N., Iuorno M.J., and Jakubowicz D.J. Strategies for the use of insulin-sensitizing drugs to treat infertility in women with polycystic ovary syndrome. Fertil Steril 77 (2002) 209-215
10. Kashyap S., Wells G., and Rosenwaks Z. Insulin-sensitizing agents as primary therapy for patients with polycystic ovarian syndrome. Hum Reprod 19 (2004) 2474-2483
11. Baillargeon J.P., Jakubowicz D.J., Iuorno M.J., et al. Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity. Fertil Steril 82 (2004) 893-902
12. Velazquez E.M., Acosta A., and Mendoza S.G. Menstrual cyclicity after metformin therapy in polycystic ovary syndrome. Obstetr Gynecol 90 (1997) 392-395
13. The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and longterm health risks related to polycystic ovary syndrome. Fertil Steril 81 (2004) 19-25
14. Balen A.H., Laven J.S.E., Tan S.L., and Dewailly D. Ultrasound assessment of the polycystic ovary: international consensus definitions. Hum Reprod Update 9 (2003) 505-514
15. Stern S.E., Williams K., Ferrannini E., DeFronzo R.A., Bogardus C., and Stern M. Identification of individuals with insulin resistance using routine clinical measurements. Diabetes 54 (2005) 333-339
16. Jayagopal V., Diver M., Kilpatrick E., Jennings P., and Atkin S. Biological variation of free androgen index and bioavailable testosterone in PCOS: implications for estimation of hyperandrogenaemia. J Clin Endocrinol Metab 88 (2003) 1528-1533
17. Dunaif A., and Thomas A. Current concepts in the polycystic ovary syndrome. Annu Rev Med 52 (2001) 401-419
18. Ibanez L., and de Zegher F. Flutamide-metformin plus an oral contraceptive (OC) for young women with polycystic ovary syndrome: switch from third to fourth-generation OC reduces body adiposity. Hum Reprod 19 (2004) 1725-1727
19. Belli S.H., Graffigna M.N., Oneto A., Otero P., Schurman L., and Levalle O.A. Effect of rosiglitazone on insulin resistance, growth factors, and reproductive disturbances in women with polycystic ovary syndrome. Fertil Steril 81 (2004) 624-629
20. Sepilian V., and Nagamani M. Effects of rosiglitazone in obese women with polycystic ovary syndrome and severe insulin resistance. J Clin Endocrinol Metab 90 (2005) 60-65
21. Azziz R., Ehrmann D., Legro R.S., et al., The PCOS/Troglitazone Study Group. Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double blind, placebo-controlled trial. J Clin Endocrinol Metab 86 (2001) 1626-1632
22. Brettenthaler N., De Geyter C., Huber P.R., and Keller U. Effect of the insulin sensitizer pioglitazone on insulin resistance, hyperandrogenism, and ovulatory dysfunction in women with polycystic ovary syndrome. J Clin Endocrinol Metab 89 (2004) 3835-3840
23. Yki-Järvinen H. Thiazolidinediones. N Engl J Med 351 (2004) 1106-1118
24. Ortega-Gonzalez C., Luna S., Hernandez L., et al. Responses of serum androgen and insulin resistance to metformin and pioglitazone in obese, insulin-resistant women with polycystic ovary syndrome. J Clin Endocrinol Metab 90 (2005) 1360-1365
25. Einhorn D., Aroda V.R., and Henry R.R. Glitazones and the management of insulin resistance: what they do and how might they be used. Endocrinol Metab Clin North Am 33 (2004) 595-616
26. Khan M.A., St. Peter J.V., and Xue J.L. A prospective, randomized comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone. Diab Care 25 (2002) 708-711
27. Kilicdag E.B., Bagis T., Zeyneloglu H.B., et al. Homocysteine levels in women with polycystic ovary syndrome treated with metformin versus rosiglitazone: a randomized study. Hum Reprod 20 (2005) 894-899
28. Mitkov M., Pehlivanov B., and Terzieva D. Combined use of metformin and ethinyl estradiol-cyproterone acetate in polycystic ovary syndrome. Eur J Obstetr Gynecol Reprod Biol 118 (2005) 209-213